Working together, for a more competitive, healthier andstronger Europe & Japan

Lars Fruergaard Jørgensen
EFPIA President

1

EFPIA’s vision: working together for a more competitive, healthier andstronger Europe and Japan
Industry contributing to patients, healthcare systems and societies overall

COMPETITIVEHEALTHIERSTRONGERTHRIVING EUROPEAN –AND JAPANESEINNOVATION ECOSYSTEMFOR MEDICINESALL PEOPLE IN EUROPE
AND JAPAN HAVE TIMELYACCESS TO WORLDLEADING CARE AND
THERAPEUTICS

A PHARMACEUTICALSECTOR THATCONTRIBUTES TO ASUSTAINABLE SOCIETY
AND ECONOMY

www.efpia.eu
C1 - Internal use22Because the healthcare sector is transforming, more than ever,meaningful patient engagement is a priority for EFPIAIN EUROPE

IN JAPAN

A Patient engagement strategy is endorsed by the EFPIA board
and is priority area under our strategic goal of ‘contributing to asustainable society and economy’
EFPIA has worked to ensure that the voice ofpatient organisations is heard across the life-cycle of a
medicine, at every decision-making point including through: EFPIA
Patient Think Tank and Innovative Medicines Initiative
We have co-created a number of collaborative projects in areas ofcommon interest such as (#DatasavesLives), HTA 360 projectTo Ensure the highest standards of ethics, EFPIA has co-created a
set of principles to govern relationships between patientorganisations and the pharmaceutical industry

3

The European-based biopharma companies have been working closely with various
governments in co-developing life-sciences strategies
FRANCEDENMARK‘France Innovation Health’ 2030 is establishedin a concerted manner between the State andthe pharmaceutical, device and diagnostic
sectors. The strategic vision is co-constructedon the basis of shared diagnosis andchallenges, and the operational follow-up of themeasures is then ensured by people from theindustrial sector with regular meetings with thedifferent ministries concerned (health, industry,research) and Macron’s office.

The interministerial mission under the PM
Elisabeth Borne on the regulation andfinancing of health products calls for a “NewDeal”, enabling an equal and sustainable
access for all patients to pharamceuticalproducts. The report believes that innovation ingeneral, and health data in particular are "keyto finding financial margins and therefore costand volume control". The mission recalls that
innovation can help control public spending incertain areas.

The Danish National Life
Sciences Council enables
continuous alignment on key
policy goals between various
stakeholders, including industry,government stakeholders, andpatient organizations.

4
C1 - Internal use

As in Europe, EFPIA is committed to working closely with Japanese
government to co-develop a pro-innovation health-ecosystem
New post-pandemic Health Policies

Pre and pandemic phase key learnings

NUMBER OF NEW CHEMICALAND BIOLOGICAL ENTITIES (2001-2020)
16013814012010080604075726461514923200-10089483119143138

As in Europe, a substantial,
high-level strategic dialogue
is needed and cansignificantly contribute to arenewed collaboration forhealth in Japan

112000-2005

2006-20102011-2015

EuropeUSAJapan

2016-2020

OthersSOURCE: SCRIP – EFPIA CALCULATIONS (ACCORDING TO NATIONALITY OF MOTHER COMPANY) ; IQVIA (MIDAS APRIL 2021)

5

Thank you!
ありがとうございました!

6
C1 - Internal use